X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
The company launched desmopressin acetate for injection in the United States as a therapeutic equivalent generic for DDAVP for treating is multi-indicated for patients with central diabetes insipidus, hemophilia A, and von willebrand’s disease (Type I).
Lead Product(s): Desmopressin Acetate
Therapeutic Area: Rare Diseases and Disorders Product Name: DDAVP-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is the first FDA-approved therapy for nocturia.
Lead Product(s): Desmopressin Acetate
Therapeutic Area: Urology Product Name: Noctiva
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Acerus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 09, 2022
Details:
Both Noctiva™ and Natesto® are highly clinically differentiated products with significant patent protection into the 2030s, that Acerus management feels could reach double-digit market share in each of these large market opportunities.
Lead Product(s): Desmopressin Acetate
Therapeutic Area: Urology Product Name: Noctiva
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Acerus Pharmaceuticals
Deal Size: $16.0 million Upfront Cash: $6.0 million
Deal Type: Agreement February 28, 2022
Details:
This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.
Lead Product(s): Desmopressin Acetate
Therapeutic Area: Urology Product Name: Nocdurna
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Antares Pharma
Deal Size: $25.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement October 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
